正體中文

  • About Us

  • News

  • Products
    • Technology Platform
    • Products

  • Production

  • Investors

  • Contact Us

News

Home News

News

Intech made co-development alliance with Twi to enter niche inhaler market of US.

2017/04/26

Intech got the permission of clinical trials for its asthma product Duasma in China.

2016/10/26

Intech got the preliminary approval and will submit the application of final approval for listing on OTC stock market soon.

2016/09/09

Intech has submitted its application for IPO, and triggered its multinational clinical trials and international business development.

2016/04/29

Intech new plant accelerates the pace and expands the capacity to fulfill the international market demand.

2015/12/23

Intech signed the license and supply agreement with China Resources Saike Pharmaceutical, both companies will form an alliance and seize the niche market.

2015/12/02

Intech iLEF MDI platform is praised widely and will move quickly in China market.

2015/10/22

Intech got the qualification report of sample testing for Duasma, an inhaler product treating Asthma, and accelerate the market expansion in Taiwan and China.

2015/09/21

Intech got the license of Duasma, an inhaler product treating Asthma, in Hong Kong and accelerate the market expansion in the area of Greater China.

2015/05/11

Intech has launched a reliever drug of asthma Synvent in Taiwan and targets the 2.6 billion global market in the future.

2015/04/07
  • 1
  • 2


About Intech
About us
History
Management team
News
Products
Technology Platform
Production
Production

Investors
Financial Information
Board of Directors
Contact Us
正體中文

Intech Biopharm Corporation © 2023 All Rights Reserved.
3F., No.36, Ln.358, Ruiguang Rd., Neihu Dist., Taipei City 114, Taiwan, R.O.C. Tel:+886-02-7721-8877 Fax:+886-02-7721-8800
华体会手机网页版登录入口 | 爱游戏网页版登录入口 | 乐鱼网页版登录入口 | 乐鱼网页版登录界面 | 开云链接官网 | 乐鱼(中国)官方网站 | 半岛网页版 | 开云官方注册 | 天行体育 |